Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: example from New Zealand
|
Vaccine
|
2018
|
|
The projected timeframe until cervical cancer elimination in Australia
|
The Lancet Public Health
|
2018
|
|
Australia on-track to be the first country to achieve cervical cancer elimination
|
HPV World
|
2018
|
|
HPV and Oropharyngeal Cancer among Indigenous Australians: Study Protocol
|
JMIR Resarch Protocols
|
2018
|
|
Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia
|
PLoS One
|
2018
|
|
How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country
|
International Journal of Cancer
|
2017
|
|
Cost-effectiveness estimates: the need for complete reporting Authors' reply
|
The Lancet Public Health
|
2017
|
|
Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program
|
The Lancet Public Health
|
2017
|
|
Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia
|
PLoS One
|
2017
|
|
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis
|
The Lancet Public Health
|
2016
|
|
Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries
|
International Journal of Cancer
|
2016
|
|
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models
|
The Lancet Public Health
|
2016
|
|
Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand
|
PLoS ONE
|
2016
|
|
Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use
|
BMC Health Services Research
|
2016
|
|
Impact of+A15 HPV sample self-collection for underscreened women in the renewed National Cervical Screening Program
|
Medical Journal of Australia
|
2016
|
|
Incremental benefits of male HPV vaccination: Accounting for inequality in population uptake
|
PLoS One
|
2014
|
|
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds
|
Health Technology Assessment
|
2014
|
|
Testing previous model predictions against new data on human papillomavirus vaccination program outcomes
|
BMC Research Notes
|
2014
|
|
Expenditure and resource utilisation for cervical screening in Australia
|
BMC Health Services Research
|
2012
|
|
Cost-effectiveness of HPV test of cure following treatment for Cervical Intraepithelial Neoplasia: Results from the NHS Sentinel Sites Study
|
BMJ
|
2012
|
|
A revision of sexual mixing matrices in models of sexually transmitted infection
|
Statistics in Medicine
|
2012
|
|
The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia
|
Vaccine
|
2011
|
|
Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies
|
Vaccine
|
2011
|
|
Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study
|
BMC Cancer
|
2011
|
|
MAVARIC a comparison of automation-assisted and manual cervical screening: a randomised controlled trial
|
Health Technology Assessment
|
2011
|
|
Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years
|
BMC Public Health
|
2010
|
|
The predicted impact of vaccination on human papillomavirus infections in Australia
|
International Journal of Cancer
|
2008
|
|